Literature DB >> 27522503

CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience.

Giuseppe Colloca1, Antonella Venturino2, Domenico Guarneri2.   

Abstract

The absolute value of carbohydrate antigen 19-9 (CA19-9) pretreatment and its reduction after chemotherapy are established prognostic variables for patients with advanced pancreatic cancer. The present study is a retrospective monoinstitutional evaluation of the prognostic role of the CA19-9 reduction and some CA19-9-related tumor kinetics parameters, such as tumor growth rate constant (G), kinetic tumor response and log ratio. Forty-one cases met the selection criteria. After 8 weeks only G reported an inverse relationship with OS (r = -0.494) that was confirmed by regression analysis (R (2) = 0.192). G after 8 weeks of chemotherapy appears as a possible surrogate end point of overall survival.

Entities:  

Keywords:  CA19-9; Chemotherapy; Pancreatic cancer; Serologic response; Tumor growth rate

Mesh：

Substances：

Year:  2016        PMID： 27522503     DOI： 10.1007/s12032-016-0817-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  36 in total

1.  Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.

Authors:  Everardo D Saad; Marcel C Machado; Dalia Wajsbrot; Roberto Abramoff; Paulo M Hoff; Jacques Tabacof; Artur Katz; Sergio D Simon; René C Gansl
Journal:  Int J Gastrointest Cancer       Date:  2002

2.  Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.

Authors:  Stefan Boeck; Michael Haas; Rüdiger P Laubender; Frank Kullmann; Christina Klose; Christiane J Bruns; Ralf Wilkowski; Petra Stieber; Stefan Holdenrieder; Hannes Buchner; Ulrich Mansmann; Volker Heinemann
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

3.  Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.

Authors:  Mitsuro Kanda; Tsutomu Fujii; Hideki Takami; Masaya Suenaga; Yoshikuni Inokawa; Suguru Yamada; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Shuji Nomoto; Yasuhiro Kodera
Journal:  Surg Today       Date:  2013-10-09       Impact factor: 2.549

4.  Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Authors:  Wilfred D Stein; James L Gulley; Jeff Schlom; Ravi A Madan; William Dahut; William D Figg; Yang-Min Ning; Phil M Arlen; Doug Price; Susan E Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2010-11-24       Impact factor: 12.531

5.  Growth rate of pancreatic adenocarcinoma: initial clinical experience.

Authors:  H Furukawa; R Iwata; N Moriyama
Journal:  Pancreas       Date:  2001-05       Impact factor: 3.327

6.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

Review 7.  Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography.

Authors:  H J Brambs; C D Claussen
Journal:  Endoscopy       Date:  1993-01       Impact factor: 10.093

8.  Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?

Authors:  J Stemmler; P Stieber; A M Szymala; A Schalhorn; M M Schermuly; R Wilkowski; T Helmberger; R Lamerz; C Stoffregen; K Niebler; M Garbrecht; V Heinemann
Journal:  Onkologie       Date:  2003-10

9.  A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk.

Authors:  Meian He; Chen Wu; Jianfeng Xu; Huan Guo; Handong Yang; Xiaomin Zhang; Jielin Sun; Dianke Yu; Li Zhou; Tao Peng; Yunfeng He; Yong Gao; Jing Yuan; Qifei Deng; Xiayun Dai; Aihua Tan; Yingying Feng; Haiying Zhang; Xinwen Min; Xiaobo Yang; Jiang Zhu; Kan Zhai; Jiang Chang; Xue Qin; Wen Tan; Yanling Hu; Mingjian Lang; Sha Tao; Yuanfeng Li; Yi Li; Junjie Feng; Dongfeng Li; Seong-Tae Kim; Shijun Zhang; Hongxing Zhang; S Lilly Zheng; Lixuan Gui; Youjie Wang; Sheng Wei; Feng Wang; Weimin Fang; Yuan Liang; Yun Zhai; Weihong Chen; Xiaoping Miao; Gangqiao Zhou; Frank B Hu; Dongxin Lin; Zengnan Mo; Tangchun Wu
Journal:  Gut       Date:  2013-01-07       Impact factor: 23.059

10.  Quantitative analysis of tumor growth rate and changes in tumor marker level: specific growth rate versus doubling time.

Authors:  Esmaeil Mehrara; Eva Forssell-Aronsson; Håkan Ahlman; Peter Bernhardt
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.